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INTRODUCTION 
 
The following project was carried out at MolGen research group of the 
Rijksuniversiteit Groningen, NL. 
The aim of this work is to provide new tools to engineer lantibiotic peptides. 
Lantibiotics are post-translationally modified antimicrobial peptides that show 
antimicrobial activity against a wide group of Gram-positive bacteria. 
To obtain antimicrobial activity lantibiotics are processed by a post-translational 
modification machiney formed by a set of enzymes. 
Lantibiotics represent a potential solution to figth multi-drugs resistant pathogens. 
Apromising way in the use of lantibiotics as new antibiotics involves a Synthetic 
Biology approach. 
Synthetic Biology aims to apply the principles of modularity and orthogonality of 
engineering to Biology. 
On lantibiotics, this means standardization of parts of the peptide or the biosynthetic 
machinery in such a way that they can be predictably combined to produce a new 
antimicrobial molecule. 
Lantibiotics structure involves two regions, a leader-peptide and a core-peptide. 
Core-peptide is the region that harbour the modifications and that possess 
antimicrobial activity. 
A leader peptide is necessary for recognition of the molecule by modification 
enzymes. 
The cleavage of the leader peptide is requested to have antimicrobial activity. 
Structure, classification and  mode of action of lantibiotics are described in the first 
chapter. 
This project involved two lantibiotics and their modification machinery: nisin and 
cinnamycin. 
 
Nisin is a lantibiotic with a rod-like structure that after modification possesses 
lanthionine and metylanthionine rings. These rings are fundamentals for its 
antimicrobial activity. 
The modification machinery of nisin involves the enzymes NisB and NisC, 
responsible for the lanthionine and methylantionine formation; NisP, necessary for 
the cleavage of the leader peptide; and NisT that transports the modified nisin out of 
the cell. 
Unlike nisin, cinnamycin has a globular structure and in addition to lanthionine and 
methylanthione ring possess others modifications, a hydroxylated aspartic acid and a 
lysinoalanine bridge. 
The modification enzymes are: CinM, the single enzyme responsible for lanthionine 
and methylantionine formation; CinX the hydroxylase; Orf7 that form the 
lysinoalanine bridge. 
The second chapter of this thesis focuses on nisin and cinnamycin structure and 
describes their modification machinery. 
The main goal of this work is to prove that cinnamycin enzyme CinM can modify 
nisin to obtain a fully modified molecule that show antimicrobial activity. 
To do that, a cinnamycin heterologous expression system was implemented in E. 
coli, confirming that cinnamycin can be produced and modified in a heterologous 
producer. 
The activity of the peptide was confirmed by the modifications on core peptide 
demonstrated by mass spectrometry analysis, and by activity tests. 
These result confirmed that CinM can be produced and work in E. coli. 
To allow modification of nisin by CinM was necessary to design a specific molecule 
formed by a chimeric leader peptide and nisin core peptide. 
The chimeric leader peptide was formed by fusion of cinnamycin leader peptide and 
nisin leader peptide, in this way CinM could recognize the cinnamycin leader and 
modify nisin. 
 
The production of this chimeric nisin and its modification by nisin system was tested 
beforehead. 
The results proved that the presence of cinnamycin leader does not affect the nisin 
production and modification, as well its activity. 
Finally, the modification of nisin by CinM was tested on the same chimeric 
molecule. 
The result showed that CinM can modify nisin, this means that a single enzyme as 
CinM can act in the same way as the combination of NisC and NisB. 
This result proves that CinM can be used to modify lantibiotics using a chimeric 
leader system, even if optimal modification conditions are to be found. 
In addition, the use of CinM open the way to the introduction of lysinoalanine 
bridge formation by Orf7 in nisin or designed substrates, because this last enzyme 
require the presence of CinM to work. 
The experiments carried out and the results are described and discussed in chapters 
three and four. 
 
 
 
 
 
  
 
 
  
 
CHAPTER 1: Lantibiotic definition and mode of action  
 
1.1 Definition of lantibiotic 
 
Lantipeptides are polycyclic peptides characterized by the presence of the thioether-
cross-linked amino acids meso-lanthionine (Lan) and (2S, 3S, 6R)-3-
methyllanthionine (Melan) [1]. 
Lantipeptides that shows antimicrobial activity are called lantibiotics. 
Small antimicrobial peptides produced by Gram-positive bacteria are named 
bacteriocins. 
Bacteriocins that do not require post-traslational modifications for their antimicrobial 
activity are classified as non-lantibiotics, whereas members of the lantibiotic group 
need modifications to show antimicrobial activity. 
Lantibiotics are produced by ribosomes as inactive pre-peptides, consisting in an N-
terminal leader-peptide and a C-terminal core-peptide part [2]. 
The modifications are carried out by lantibiotic-specific modification enzymes, that 
requires the presence of a leader peptide to recognize the target molecule. 
The modifications involves only the core-peptide part, in which most of the serine 
(Ser) and threonine (Thr) residues are dehydrated to dehydroalanine (Dha) and 
dehydrobutyrine (Dhb) respectively. 
Subsequently this dehydroresidues are coupled to cysteines (Cys) residues, this leads 
to the formation of (methyl)lanthionine rings. This step is generally called cyclization. 
In the end, the cleavage of the leader peptide by dedicated protease is necessary to 
obtain the active compound. 
 
 
Fig 1: General representation of ribosomally synthetsized natural product (RNP) 
biosynthesis.Xn* represent modified amino acidic residues 
 
On the basis of the biosynthetic machinery involved in the formation of 
(methyl)lanthionine rings, is possible to define four classes of lantipeptides. 
For class I, two distinct enzymes, the dehydratase LanB and the cyclase LanC, 
perform Ser/Thr dehydration and cyclization respectively. 
The term “Lan” is a general abbreviation for proteins involved in lantibiotic 
biosynthesis. 
A member of Class I lantibiotic is nisin. 
For class II, these reactions are carried out by a single bifunctional enzyme, LanM, 
containing both the dehydratase (N-terminal part) and cyclase (C-terminal part) 
domains. 
This is the case of cinnamycin. 
Class III lantibiotics are formed by two subunits called α-peptide and β-peptide that 
are linked together. 
Lantipeptides that are members of Class III, are modified by a trifunctional synthetase, 
containing an N-terminal lyase domain, a central kinase domain, and a putative 
cyclase domain in the C-terminal part. 
 
For this last domain is used the term putative because it lacks many of the conserved 
active-site motif found in LanM and LanC ezymes. 
In the end, recently identified Class IV lantipeptides, are modified by a single enzyme 
similar as Class III synthetase, LanL. This enzyme contains the lyase domain and 
kinase domain as the Class III enzyme, but its C-terminal cyclase domain is analogous 
to LanC  
Fig. 2: Schematic representation of the four classes of lantipeptides modification enzymes. 
Highlighted part represent conserved motifs.  
 
1.2 Clinical use of lantibiotics 
 
Due to an increasing resistance of bacteria to available antibiotics, there is an urgent 
need to search for substances active against multidrugs resistant pathogens [2]. 
In the last years, the increase of multidrug resistant bacteria, especially in hospital 
environments, has caused an increasing concern in medicine. 
 
Some of this multidrug resistant bacteria are: methicillin-resistant Staphilococcus 
aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), third generation 
cephalosporin-resistant E. coli. 
This topic has become of major interest in antibacterial therapy, highlighting the need 
of new ways to treat infections. 
In literature is possible to find several approaches to tackle down this problem, such 
as isolation of infected patients in hospitals, reduction of non-human antibiotics, 
rational use of antimicrobials, or phage therapy [6-8]. 
Another way to fight this growing threat is to find new antibiotics with a new 
mechanism of action. 
Under this respect a new approach in the research of antibacterial agents is needed, 
because the research in traditional antibiotics did not provide good results. 
According to a recent report of European Medicines Agency, only 15 compounds of 
167, investigated in clinical trial, shows a new mechanism of action or involve a new 
target. 
The situation is even worse for Gram-negative bacteria, where only 2 of the 167 
compounds had a novel target or mechanism of action. 
This results lead to a reduced interest from pharmaceutical sector (1.6% of the total 
molecules under development in 2004), and should be compensated by investments 
from public funds [9]. 
It has already been shown that some lantibiotics exhibit activity against antibiotic-
resistant pathogens at nanomolar concentrations, so at concentration similar to 
commercial antibiotics, targeting a different compound of bacterial membrane 
compared with traditional antibodies. 
Clinical applications of lantibiotics are currently of great interest. 
Lantibiotics possess potent activity against several clinically relevant Gram-positive 
bacteria, such as Staphylococcus, Streptococcus, Enterococcus, but also against 
Gram-negative bacteria as Neisseria and Helicobacter. 
 
Currently there are several lantibiotics in clinical and preclinical development such as 
duramicycin for the treatment of cystic fibrosis-associated pneumonias, mersacidin, 
that shows activity against methicillin-resistant Streptococcus aureus strains, and 
lacticin 3147 proved to be a successful antimicrobial agent against vancomycin-
resistant Enterococcus faecalis andpenicillin-resistant Streptococcus pneumonia. 
 
1.3 Mode of action of lantibiotics 
 
The mechanism of action by which lantibiotics exert bactericidal activity has been 
studied only in few cases, but most of this bactericidal peptides are believed to inhibit 
cell wall biosynthesis and/or form pores through the membrane, leading to cell 
disruption. 
Target of lantibiotics seems to be Lipid II, an amphipathic peptidoglycan precursor 
molecule involved in the synthesis of the cell wall of bacteria. 
Lipid II is responsible to deliver the complete peptidoglycan,formed at cytoplasmic 
side of the membrane, to the extracellular side (Fig 3) [4].  
 
 
 
Fig 3: Schematic representation of cell wall biosynthesis steps.  GLCNAc (N-
acetylglucosamine) and MurNAc (N-acetylmuramic acid)are compounds of peptidoglycan 
involved in cell wall synthesis 
 
Binding of Lipid II leads to inhibition of transglycosylation reaction, necessary in the 
synthesis of peptidioglycan and therefore in the synthesis of the cell wall. 
Bound Lipid II are sequestered from the cell wall division site (septum) and 
translocate in a non-functional locations, in this way the cell wall biosynthesis is 
stopped.[3] 
As mentioned above, the other mechanism of action for lantibiotics involves the 
formation of pores through the membrane of bacteria. 
This mechanism has been extensively studied for the Class I lantibiotic nisin. 
The first two rings in nisin, called A and B, and formed by a Lan and a MeLan 
respectively, can bind the pyrophosphate portion of Lipid II (Fig 4). 
 
 
 
 
 
Fig 4: Structure of Lipid II. The red bars indicate the 
minimal binding sites in Lipid II of glycopeptide 
antibiotics (1), nisin (2), ramoplanin (3) and mersacidin 
(4). 
GlcNAc (N-acetylglucosamine); MurNAc (N-
acetylmuramic acid). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As the A and B rings are conserved in most of Class I lantibiotics, this mode of action 
is credited to other class I lantipeptides. 
Once the two rings bind Lipid II, nisin is able to insert its tail into the membrane. 
A group of eight nisin, and four Lipid II, form a stable pore that leads to the loss of 
intracellular compounds in the extracellular environment and consequently to the 
death of the bacteria (Fig 6) [3]. 
 
 
 
 
Fig 6: Schematic representation of pore-formation nisin mechanism. (a): nisin reach the 
extracellular side of the membrane; (b): nisin rings A and B bind the pyrophosphates of 
LipidII; (c): transmembrane insertion of nisin; (d): four nisin bind four Lipid II, and four 
additional nisin are recruited for pore formation. 
 
As mentioned above, and shown in Fig. 5, nisin can bind the Lipid II at pyrophosphate 
level. General glycopeptide antibiotics, such as vancomycin, can bind Lipid II at level 
of the pentapeptide. This kind of binding is related to the specific sequence of this 
oligopeptide. 
This means that changes in the amino acidic sequence can compromise the binding. 
Bacteria can change this sequence and thus develop resistance to general glycopeptide 
antibiotics. On the other hand, the pyrophosphates are a fundamental mojeties of Lipid 
II and difficult to replace. This could represent a potential advantage for using 
lantibiotics, as bacteria cannot easily develop resistance. This is  proved from the fact 
that in 50 years of use of nisin as food preservative no significant resistance has been 
observed. 
 
Some kind of resistance mechanism has been detected, as an increising in the cell wall 
thickness in an attempt to reduce the access to the Lipid II, but this does not lead to a 
significant decreasing of nisin activity. 
As nisin, classII lantibiotics (e.s. mersacidin) kill bacteria with a mechanism that 
inhibits cell wall replication by binding Lipid II, but this mechanismdoes not involve 
pore formation. 
The binding site of mersacidin involves the GLcNAc sugar, but cannot bind it in 
LipidII. 
The mechanism of Lipid II binding seems to be related with positive charge, in 
particular seems that this mechanism is dependent to the bivalent ion Ca2+ that is 
responsible for the formation of a bridge between the lantibiotic and the sugar of Lipid 
II [4]. 
Not all the class II lantibiotics act in this way, cinnamycin e.g. does not target Lipid 
II. 
Mode of action of Class III lantibiotics involves both the subunits. 
The α-peptide behave like mersacidin, binding the LipidII then, the β-peptide is 
recruited to form pores. 
An example of this lantibiotics is haloduracin. 
In this case, a complex formed by a Lipid II, two α-peptide and two β-peptide is 
necessary for the pore formation. 
This mode of action explains why a single subunit of a two component lantibiotic 
shows low or no activity. [1]. 
The literaturereports of other lantibiotics, such as Pep5 and epilacin K7, that form 
pores without the binding of Lipid II, suggesting a specific but alternative molecular 
target [10]. 
Another advantage in the use of antibiotics targeting Lipid II is the low toxicity in 
human, due to the fact that Lipid II production is restricted to bacteria. 
 
However, there are still obstacles that must be overcome before lantibiotics can be 
introduced in clinical applications. 
For example, nisin shows poor pharmacokinetic that represents the main impediment 
to its clinical development. 
Anyway, the development of nisin as therapeutic molecule can benefit of the large 
amount of information collected from more 50 years of usage of nisin as food 
preservative, for example, this information can be used on issues relating stability and 
conditions of use [4]. 
In conclusion, the available data support the great capabilities of lantibiotics as potent 
antimicrobials with a novel mechanism of action [5]. 
 
1.3.1 Effect of the presence of thioether bridges in lantibiotics 
 
As mentioned before, lantibiotics have still to overcome some obstacles before their 
clinical use is confirmed. 
On the other hand, lantibiotics have a characteristic that is very important for a 
therapeutic peptide: the presence of thioether-bridges. 
The main limitation in the application of therapeutic peptides is their rapid 
degradation by proteases. 
A strategy to prolong the clearance of these peptides is to bind them to a protein as 
albumin. 
This problem does not affect lantibiotics, because of the presence of thioether-bridges 
that confer strong resistance against proteolitic degradation [6]. 
In lantibiotics, thioether-bridges are present in the amino acids lanthionine and 
methylanthionine, introduced as post-traslational modifications. 
Therefore, Lan and MeLan rings are useful both for the activity and for the resistance 
against proteolitic degradation. 
 
In lantibiotics the Lan and MeLan formation follow this steps: 1) dehydratation of 
serines (Ser) and threonines (Thr); 2) resulting dehydroalanines and dehydrobutyrines 
are coupled to cysteines. This process is catalized by a cyclase enzyme (Fig 7) [6]. 
 
 
 
Fig 7: Schematic representation of thioether-bridge formation. 
 
Resistance against proteases gives the advantage that a higher concentration of 
therapeutic peptide can be reached in the body and can be kept for longer time. 
More important, proteolitic stability prevent the formation of toxic compounds from 
lysate peptides. 
The presence of thioether-bridges seems to open the way to the production of oral 
delivery peptide drugs. 
This kind of delivery is very difficult to reach in peptide drugs that do not contain 
thioethers links, but seems to be possible in those that have these bridges, as shown 
 
for thioether-bridged angiotensin, that could be successfully delivered both orally and 
airborne [5].   
 
 
1.4 Strategies to develop new lantibiotics. 
 
As stated in the previous paragraph, the use of lantibiotics represents a valid and novel 
strategy to fight the growing problem of multi-resistant pathogens. 
To increase the success of lantibiotics as new drugs several strategies can be used. 
For example exploiting the possibility to realize fusion leader-peptide and the 
substrate tolerance for modification enzymes, the design of novel lantibiotics or an 
improved activity of bioactive compounds is possible. 
In this paragraph possible strategies in the discover of new lantibiotics are described, 
including both a natural and a synthetic biology approach. Furthermore, methods to 
improve activity of these lantibiotics, as additional modifications or mutagenesis, are 
illustrated. 
 
1.4.1 Traditional approach: discover new lantibiotics using wild-type producers 
 
The traditional approach to search new potential antibiotic compounds is based on the 
isolation of producer organisms from diverse habitats. 
After isolation of the producer, the next step is to check the antimicrobial activity. 
The most common way to do that is an agar diffusion assay (or activity test). 
With this assay is possible to check if the producer actually can produce antimicrobial 
molecules (lantipeptides in our case), and this is confirmed by an inhibition of growth 
of the indicator strain on the plate (Fig 7). 
For this kind of assay two variable are to be taken into account: the indicator strain 
and the conditions for the growth of the producer. 
 
The number and diversity of indicator strains that can be tested is a limitation, but is 
also true that we can limit this number selecting only strain suitable for certain 
application. 
Also, finding the growth condition in which the producer can express the lantibiotic 
is not an easy task. [5] 
If areas of growth inhibitions are detected is necessary to check if the inhibition 
actually depends from the antimicrobial peptide or if it is related to others substances, 
for example catabolities as organic acids. 
Therefore, additional steps are necessary to check the antimicrobial molecule, but 
anyway this method is still a good strategy to screen potential producers. 
The main disadvantage of this kind of approach is the wide screening area that has to 
be covered, which lead to a high demand of resources. This point can be partially 
overcome by automatic high throughput screening systems [5]. 
On the other hand, the advantage is that identified antimicrobial compound are already 
been selected in the appropriate growth conditions. 
 
 
 
Fig 7: Example of activity test. In this case the activity of cinnamycin samples against 
Bacillus subtilis LH45 (indicator strain) is shown on LB-agar plate. 
 
 
1.4.2In silico genomic mining-tools to discover new lantibiotics 
 
An alternative way to discover new lantibiotics involve the analysis of the genome of 
potential producers. 
Anyway, lantibiotic structural genes (genes that codify LanA) are too small and show 
low homology to use a similarity oriented search. 
Instead of searching for homology of structural genes, a better strategy is search for 
homology for modification enzymes, because of their larger size and conserved 
domains. 
Literature report that structural genes for lantibiotics are surrounded by “Open 
Reading Frames” (ORFs) for modification enzymes. 
 
That means that searching in the genome of a potential producer for a modification 
enzyme gene can lead to the entire gene cluster for the expression of the lantibiotic. 
The use ofin silico mining tools, such as “Bagel2” and “Bagel3” softwares developed 
by “Molgen” group of the Groningen University, is necessary to this aim. 
This searching engine allow the identification in the genome of a gene cluster related 
to the production of lantibiotics , considering the structure of the putative structural 
gene, the surrounding ORFs and their homology to modification enzymes. 
This kind of strategy allow to check exotic and non-culturable bacteria, and if a 
positive result is found is possible to try heterologous expression. 
Other application of in silicoanalysis, oriented to microbial ecology, permit to restrict 
the environments to screen to find new potential producers. 
 
1.4.3 Improve the bioactivity through mutagenesis 
 
Once a novel lantibiotic has been defined it’s possible to improve its properties as 
stability, potency or spectrum using mutagenesis. 
That means the replacement one or more amino acids in the peptide sequence. 
Mutagenesis can be also use to better understand the lantibiotic’s mechanism of 
action, its maturation process and the bacterial immunity system. 
Experiments carried out on the leader peptide highlight the role of this portion on the 
maturation step, because after mutation the modification enzymes could not more 
recognize the leader and modify the core peptide. 
However, point mutation can improve molecules, this is the case of nisin Z, in which 
after a substitution was observed an improved stability and solubility without 
decreasing the activity. This was possible by an insertion of a positively charge amino 
acids in the first ring (Fig 8). 
Nowadays, it is possible obtain libraries of mutants lantibiotics, with all the possible 
point mutation, or even with several mutation at the same time, and to test 
 
thesecompounds with high throughput screening systems to identify variants with 
higher expression level, better stability or specific bioactivity. 
Of course this strategy can be used on wild type lantibiotics as well as on new 
synthetized ones. 
 
Fig 8:  Nisin Z with possible mutations. Red circles indicates improved activity, blue circle 
indicates improved physiochemical proprieties. 
 
1.4.4 Synthetic Biology approach 
 
Synthetic Biology aims to apply the principles of modularity and orthogonallity of 
engineering to Biology. 
Thus, the isolation of parts of the peptide or the biosynthetic machinery should be 
standardized in such a way that they can be predictably combined to produce a new 
antimicrobial molecule [5]. 
As mentioned above, modification enzymes of lantibiotics can modify a wide range 
of substrate peptides as long as they are linked to the leader peptide that is necessary 
for the recognition from the enzymes. 
This point has been reported for nisin modification enzymes nisB, nisC and nisT. 
 
In the chapter 3 of this thesis the modification of nisin with a chimeric leader peptide 
is reported. The synthetic leader is formed by the fusion of cinnamycin and nisin 
leaders by the class LanM modification enzyme CinM, from cinnamycin modification 
machinery. 
Indeed, it has been proved that “silent” lantibiotics from S. pneumoniae,can be 
produced and modified by nisBCT in L.lactis, thusin a heterologous host, if the core-
peptide is linked to nisin leader. 
This means that the enzymes are able not only to dehydrate and cyclize the peptide, 
but also to match dehydroamino acids and cysteines in the correct way. 
This is a clear example of modularity applied to lantibiotics production. 
Heterologous expression allow to produce lantibiotics of non-culturable bacteria 
without engineering the original producer. 
In addition, heterologous expression of lantibiotics modified by nisin system in E.coli 
has been reported. 
In addition to the characteristic lanthionine and methilantionine, lantibiotics carry 
additional post-translational modification important for stability and modification, 
such as lysinoalanine bridge in cinnamycin. 
Exploiting the concept of modularity it is possible to introduce theseadditional 
modifications of some lantibiotics to hypermodify existing molecules, and confer to 
them improved bioactivity or new proprieties. 
However,it is necessary to characterize this modification enzymes in order to use them 
in a rational and predictable way. 
Modularity in lantibiotics is not only referred to leader peptide, but also to the core 
peptide sequence. 
Three different regions can be described in nisin: 1)a  leader peptide that leads the 
modification enzymes; 2) a Lipid II binding domain, formed by the first two rings of 
nisin; 3) a membrane insertion tail. 
 
That means that is theoretically possible to design a lantibiotic with the Lipid II 
binding domain from nisin and a C-terminal tail to introduce additional post-
traslational modification to create a novel molecule. 
Modularity is present also in Class III lantibiotics, in which one subunit is necessary 
to bind Lipid II and the other is necessary for pore formation. 
Moreover, combination of lantibiotics with traditional antibiotic could represent a 
valid strategy. 
In vitrocombination of nisin with vancomycin via chemical semi-synthesis has been 
reported, and improved activity was detected for vancomycin[11]. 
The possibilities in design of novel lantibiotics with a synthetic biology approach are 
enormous because the number of combinations is very high, and can be raised with 
the discover of new lantibiotics and the modification by mutagenesis method. 
This is particularly true if we consider the possibility to introduce non-canonical 
amino acids in the sequence of lantibiotics. 
These non-canonical amino acids can allow introduction of new properties for the 
peptides. 
In conclusion, all the strategies described above should be combined to obtain a 
considerable improvement in the research of new lantibiotics (Fig8). 
 
 
Fig 8: Representation of the possible strategy in the develop of new lantibiotics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2:Analysis of the lantibiotics Nisin and 
Cinnamycin 
 
The project reported in this work involves two lantipeptides, the class I lantibiotic 
nisin, and the class II lantibiotic cinnamycin. 
In this chapter, structure, modification machinery and mode of action of these two 
lantibiotics are described. 
Furthermore, some examples of application of synthetic biology approach on nisin are 
reported. 
 
2.1 Structure, biosynthesis, modification machinery of nisin. Design of 
new lantibiotics through a Synthetic Biology approach 
 
Nisin is a class I lantibiotic produced by Lactococcus lactis, is one of the oldest know 
antibiotic compounds, and shows antimicrobial activity against Gram-positive 
bacteria. 
The genes necessary for nisin biosynthesis process - that involves production, 
maturation, immunity and regulation - are located in a conjugative transposon [20]. 
Nisin was used as food preservative for 50 years, and its high efficiency makes it one 
of only few commercial applied lantibiotics. 
Target for nisin antimicrobial activity are Gram-positive bacteria such as Bacillus 
cerus, Listeria monocytogenes, Enterococci, Staphylococci and Streptococci. 
For this very high antimicrobial activity, nisin has been proposed to be used as model 
to develop new antibiotics. 
Belonging to class I lantibiotics, nisin harbours thioether bridges in the Lan and 
MeLan resiudues, introduced after the action of the modification enzymes NisB and 
NisC. 
 
In the following paragraphs biosynthesis, modification machinery and nisin role in 
developing of new lantibiotics through a Synthetic Biology approach are described. 
 
 
 
2.2.1 Biosynthesis of nisin. 
 
Nisin biosynthetic genes are organized in four operons, nisABTCPIRK, nisI, nisRK 
and nisFEG.  
Nisin precursor peptide is encoded in the gene nisA, the result of the translation of this 
gene is a peptide of 57 aminoacidic(a.a.) residues. 
To obtain the mature lantibiotic is necessary that the modification machinery 
processes the precursor peptide. 
The modification system is encoded in the four genes nisB,nisC,nisT,nisP. 
The first one encodes the dehydratase NisB, responsible for the dehydration of three 
serine and five threonine. 
Some of this dehydrated residues are coupled with cysteins by the cyclase NisC. 
This result in the formation of one lanthionine and four methyllantionine, and also 
one dehydrobutyrine and two dehydroalanines that are not coupled with cysteins. 
The next step in the biosynthesis of nisin is the exportation of the modified molecule 
through the membrane. 
This process is carred out by the transporter NisT, an ABC-type transporter [21]. 
Both for the modification and for transportation the presence of the leader peptide is 
necessary for the enzymes to recognize the substrate molecule. 
The leader peptide is a peptide of 23 a.a., and until it is binding the modified nisin the 
molecule does not show any activity. 
Thus, the last step involves the cleavage of the leader peptide. 
This process is carried out by the membrane protein NisP. 
 
The mature nisin is also capable to induce the complex NisRK, the system that 
regulates the transcription of nisin gene cluster [20]. 
The analyis of nisin transposon (Fig. 9) highlights the presence of a regulation operon, 
formed by nisRK, and an immunity operon formed by nisI and nisFEG. 
 
 
 
Fig 9: Transcriptional organization of nisin biosynthetic gene cluster. 
 
The regulatory system for nisin biosynthesis is a two-component system, formed by 
NisR and NisK. 
NisK is a histidine sensor kinase that is located in the extracellular side of the 
membrane and act as receptor for fully matured nisin. 
The binding of NisK with nisin initiate a signal cascade, that starts with the auto-
phosphorylation of NisK. 
Subsequently, the phosphate is transferred to NisR, which is a transcriptional activator 
that binds the promoter regions of nisABCPRK and nisFEG. This induces the 
transcription of genes required for nisin biosynthesis and immunity. 
The promoter of nisRK was shown to be independent from nisin regulation and the 
two genes to be constitutively expressed. 
This system provide a tight regulation of gene expression, for this reason nisin-
controlled expression system (NICE) [22]  were developed and used to control 
overexpression of protein in heterologous expression systems. 
Lactococcus lactishas developed an immunity system against the bactericidal activity 
of nisin itself. 
 
The immunity system consist in a two-component complex made by the lipoprotein 
NisI and the ABC-type transporter NisFEG [23]. 
The two components strongly interact to confer immunity as proved by the fact that 
each component alone provide 5-20% of the total immunity level. 
NisI is a lipoprotein anchored on the extracellular side of the membrane, but also free 
NisI was detected. 
The function of NisI is to interact with nisin by binding it and avoid that nisin itself 
can target the Lipid II of the membrane. 
NisFEG form a transporter system that has the role to export nisin from the 
cytoplasmatic side of the membrane. 
The two systems interact because NisFEG can provide high local concentration region 
for nisin, so that NisI can easily intercept nisin and avoid its movement in the 
extracellular environment [20]. 
In the figure below the biosynthetic system of nisin is shown. 
 
 
 
Fig 10: Representation of nisin biosynthetic system. P in the blue circle indicates the 
phosphorylation of NisK and NisR. 
 
 
2.2.2 Analysis of nisin structure 
 
After modification nisin is a peptide of 31 amino acids containing one lanthionine ring 
and four methyllanthionine rings, plus two dehydroalanine and one dehydrobutyrine. 
The five rings on nisin molecule are named as A, B, C, D, and E starting from the N-
terminal side to the C-terminal side of the molecule. 
The main part of nisin consist of the lanthionine ring A, and the two methyllanthionine 
rings B, C. This part of the molecule is linked by a “hinge” region to two intertwined 
double methyllanthione rings D and E. 
Thus, nisin shows as a rod-like molecule with a hinge region that confer flexibility to 
the total structure, and also the two parts are both quite flexible. 
 
It is remarkable that rings A, B and C share the feature that hydrophobic part is 
situated opposite to the thioether bonds. The hydrophobic part is composed of the 
residues Ile4, Leu6, Pro9, Leu16 and Mey17 whereas the hydrophilic Lys12 is located 
at the opposite face [20]. 
Taken together, the molecule is amphipathic in two ways: first, most of the residues 
in the N-terminal part are hydrophobic and only a single charged residue is present 
(Lys12), whereas the charged and hydrophilic amino acids are mainly located in the 
C-terminal half of the molecule. 
Secondly, both the N-sided domain, with rings A, B and C as well the C-sided domain, 
containing rings D and E, have a hydrophobic and hydrophilic side [20]. 
Nisin amino acidic sequence and structure is shown in the figure below. 
 
(a) 
 
 
 
                                                                                                                             (b)  
Figure 11: (a) Structure of fully modified nisin. Red regions represent dehydrobutyrines and 
dehydroalanines involved in Lan and MeLan formation. Blue regions represent cysteines 
involved in Lan and MeLan formation. Green regions are dehydroalanines. Purple region is 
dehydrobutyrine. 
(b) Amino acidic sequence of fully modified nisin. 
 
 
 
2.2.3 Nisin modification machinery 
 
Nisin modification machinery is composed by four enzymes: the dehydratase NisB, 
the cyclase NisC, the ABC-transporter type NisT and the protease NisP. 
All the modification steps seems to be carried out in proximity of the membrane. 
This was dimostrated by immunoprecipitation assay [24], furthermore it was 
demonstrated that physical interaction between the modification enzymes is requested 
for the modification of nisin pre-peptide. 
However, in vitrostudies show that the modification enzymes can work separately, 
this means that the lanthionine sintetase complex, formed by all four modification 
enzymes, is not a prerequisite for functioning of any of the modification and transport 
enzymes, and it is likely highly unstable and transient in nature [20]. 
This means that the single modification enzymes canbe use separately to modify 
lantibiotics using a synthetic biology approach, exploiting the not strict specificity of 
these enzymes for their substrate. 
It was demonstrated that the overexpression of nisBCT gene leads to insertion of Lan 
and MeLan rings in non-lantibiotic peptides if they are linked to nisin leader. 
This proves that nisin modification enzymes do not have highly specificity and that 
the main prerequisite for modification is the presence of the leader peptide upstream 
the substrate. 
Figure 12 show nisin modification steps and lanthionine sintetase complex located in 
the cytoplasmic side of the membrane. 
 
 
 
 
 
Figure 12: Nisin modification steps and lanthionine sintetase complex. 
 
 
 
NisB, a protein of 117.5 kDa, is the dehydratase responsible for the dehydratation of 
Ser and Thr residues in the nisin core-peptide. 
This was proved by the inhibition of nisBgene. This operation leads to a complete loss 
of nisin production. Furthermore, overexpression of this enzyme rises the efficiency 
of dehydratation in nisin. 
To carry out its function NisB requires the presence of the leader peptide. 
Furthermore, it was proved that NisB could dehydrate Ser and Thr also in non-
lantibiotic peptides, showing a relaxed substrate specificity. 
Apparently the substrate specificity is related to the amino acidic residues near Ser 
and Thr residues. 
Studies demonstrates that the nature of residues close to dehydrated serine and 
dehydrated threonine may influence the dehydratation step [20]. 
These residues should be surrounded by hydrophobic residues to obtain the 
dehydratation of Ser residues.This is the main limitation for NisB substrates. 
 
NisC is the cyclase that carry out the coupling of dehydrate residues with free cysteine, 
it is a 47.9 kDa protein. 
Thus, the ring formation is lead by NisC and all the rings are oriented in the same 
manner, from N-terminal side, where the dehydro residue is located, to C-terminal 
side where the cysteine is positioned. 
The role of NisC was confirmed by knoking out this gene in nisin gene cluster. This 
operation leads to the production of nisin with dehydro- residues without lanthionine 
and menthyllanthionine rings. 
This proves that NisC is fundamental in cyclization. 
It was also proved that NisC can work separately from the other modification 
enzymes. 
It was demonstrated that NisC need the presence of the leader peptide to carry out its 
function. 
 
So, as for NisB the leader peptide is fundamental, and seems that NisC can recognize 
the leader by a specific region formed by hydrophobic and negatively charges residues 
that form a channel in which the leader peptide is supposed to be trapped. 
 
NisT is an ABC half-transporter that consist of putative α-helices that crosses the 
cytoplasmic membrane five times and a hydrophilic nucleotide-binding domain that 
binds ATP needed to energize the transport. 
A typical ABC transporter includes two modules, i.e., two trans-membrane segments 
and two nucleotide-binding domains. 
Therefore, NisT is an half ABC transporter and most likely requires another half-
transporter to form an active unit[20]. 
This putative partner is likely another NisT. 
The function of NisT was confirmed bythe  knock out of the gene nisT.As a result the 
secretion of nisin was inhibit. 
It was also proved that NisT can transport unmodified or partially modified nisin, but 
also non-lantibiotic peptides if this are fused with the nisin leader sequence. 
 
NisP is the protease that carry out the cleavage of nisin leader peptide. 
This was proved by knocking out the gene encoding NisP. 
As a result, no active compound was detected because the cleavage of the leader is 
necessaryto obtain active nisin. 
The activity was restored by incubation with cells expressing NisP. 
NisP contain a Sec-signal in the N-terminal side, that is likely responsible for targeting 
and transporting NisP out of the cell via Sec pathway. 
NisP contains also a C-terminally located LPXTG sequence, that suggests its 
anchoring to the cell surface [20]. 
 
NisP can cleave only the nisin leader peptide, furthermore neither unmodified nor 
dehydrated pre-nisin could be cleaved by NisP, indicating that one or more thioether 
rings are required for its activity [25]. 
 
2.2.3 Use of nisin and nisin modification enzymes in synthetic biology 
 
As mentioned in the previous chapter, Synthetic Biology represent a valid strategy in 
the design of new lantibiotics. 
The Synthetic Biology approach is exploiting the relaxed substrate specificity of 
enzymes involved in lantibiotic modification, and also the modular structure of 
lantibiotics themselves. 
At least two separate modules are detectable in latibiotic, a leader peptide and a core 
peptide. The first one is involved in the recognition of the molecule from modification 
enzymes. 
Using this peculiarity it is possible design non-lantibiotic peptides fused with a leader 
peptide that can be modified by modification enzymes. 
It is also possible to introduce in a given lantibiotic post-translational modifications 
that belong to other lantipeptides. 
The following are example of use of Synthetic Biology in the modification of 
lantibiotics. 
The first one describe the use of nisin modification machinery in the production of a 
two-component lantibiotic of S.pneumoniae, whereas the second one shows the 
possibility of using modification enzymes from different lantibiotics to design novel 
molecules. 
The first example is reported in [2], and reports the expression of a class II two-
component lantibiotic from S.pneumoniaeusing the nisin modification machinery. 
 
To do that it was necessary toisolate the gene encoding for the lantibiotic peptide and 
to modifyit to obtain a gene that encodes the fusion of nisin leader peptide with the 
two-component lantibiotic peptide. 
Then the overexpression of  this novel gene and of the nisBCTgenes was performed. 
The peptide was secreted out and found in the supernatant of the culture, meaning that 
the transporter nisT can export the peptide. 
Mass spectrometry analysis dimostrated the presence and partial localization of 
multiple dehydratated serines and/or threonines and (methyl)lanthionines in both 
peptides. 
Furthermore, after the cleavage of the leader peptide from both the components 
antimicrobial activity against Micrococcus flavuswas detected. 
These results proved that the nisin modification machinery can be succefully used to 
modify and produce other antimicrobially active lantibiotics, and confirm the validity 
of the synthetic biology approach. 
 
The second example is reported in [26] and is related with the design and production 
of novel lantibiotics using a combination of different lantibiotic modification 
enzymes. 
The specific results highlight:i)the modification of the lantibiotic gallidermin by nisin 
modification enzymes NisBTC and gallidermin modification enzyme GdmD ; ii) the 
design and production of a novel lantibiotic formed by the nisin region containing 
rings ABC and a gallidermin tail. This hybrid molecule was modified by the 
combination of NisBTC and GdmD; iii) the design and production of modified nisin 
by introduction of a modification carried out by lacticin modification enzyme LntJ. 
GdmD is responsible for C-terminal decarboxylation, and LntJ is a reductase that 
stereospecifically converts dehydroalanine in D-alanine. 
The modification and transport of this molecule was proved by heterologous 
expression in L.lactis, this results provide a plug and play system that can be used to 
 
select different sets of modification enzymes to work on diverse, specifically designed 
substrates, with the aim to obtain new to nature molecules with antimicrobial activity 
and/or new physicochemical proprieties. 
The representation of the system is shown in figure 13. 
 
 
 
 
Figure 13: Schematic representation of the synthetic biology plug and play system for the 
design and production of new to nature lantibiotic. 
 
2.2 Structure, mode of action and modification machinery of the class 
II lantibiotic cinnamycin 
 
 
Cinnamycin is an antibiotic peptide produced by several Streptomyces strains, 
including Streptomyces cinnamoneus DSM 40005 [13]. 
Cinnamycin belongs to lantibiotic group as it carries lanthionine and 
methyllanthioninebridges. 
As in other lantibiotics, these bridges are formed from dehydro serine and threonine 
residues, coupled with cysteines. 
These modifications are carried out by a LanM modification enzyme, called CinM, 
given that cinnamycin belongs to class II lantibiotics. 
Unlike nisin or others class I lantibiotics, cinnamycin possesses other post-
translational modification. 
Cinnamycin contains a β-hydroxy-aspartate residue and a lysinoalanine bridge (Lal). 
The hydroxylation of the aspartic acid residue (Asp) is carried out by the modification 
enzyme CinX and the formation of the Lal bridge is made by the small enzyme Orf7. 
Class II lantibiotics are less studied and usually have globular and inflexible tertiary 
structure (Fig 14), unlike the class I lantibiotics that are more flexible and have linear 
structure [14]. 
Another difference between class I molecules as nisin and class II lantibiotics as 
cinnamycin is in the mode of action. 
As mentioned in the previous chapter, class I lantibiotics exercise their antimicrobial 
activity interacting with Lipid II of the cell wall, this generally lead to pore formation. 
Some class II lantibiotics as cinnamycin and duramycin seems to exercise their 
activity binding enzymes involved in the cell wall biosynthesis. 
Similar to other lantibiotics the non-mature peptide is formed by the fusion of a leader 
peptide and a core peptide. 
The core peptide is a 19a.a.-long peptide, and it is the portion that harbour the 
lanthionine and methyllantiones residues, and the other post-translational 
modification. 
 
The leader peptide is a 59a.a.-sequence, a very long sequence if compared to leader 
peptide of others lantibiotics, especially in class I. 
The leader peptide is important for the modification enzymes to recognize their target. 
To obtain the active compound the cleavage of the leader is necessary. 
Unlike nisin, it seems that there is not a dedicated protease for this taskin the 
cinnamycin gene cluster. 
Therefore, it seems that the last three amino acids, “AFA”, of the leader are involved 
in the cleavage, fitting with the “AXA” motif recognized by type I signal peptidases 
of the general secretory pathway (Sec) [13]. 
This “AFA” sequence will be taken into account in the heterologous expression of 
cinnamycin in E.coli (described in chapter 3), to engineer the cleavage of the leader 
peptide. 
 
 
Fig 14: Schematic structure of cinnamycin. MeLan bridges are shown in green. Lan bridge 
is shown in pink. Blue is used to label the Lal bridge. Red is used to label the hydroxylation 
of Asp. 
 
2.2.1 Analysis of the cinnamycin gene cluster 
 
The study of the gene cluster involved in the expression of cinnamycin in S. 
cinnamoneumwas possiblethanks to genomic analysis tools[13]. 
The schematic representation of this cluster is illustrated in Fig 15. 
 
The genome contains 21 genes, but it is not yet clear which is the functionfor some of 
them. 
The function of each gene was studied through a homology approach, thus searching 
proteins similar to those encoded in the cin gene cluster. 
Most lantibiotic gene clusters contain the following genes: i) lanA, the lantibiotic 
prepeptide structural gene; ii) lanBC or lanM, the genes that encodes the enzyme for 
dehydratation an cyclization of dehydrated serine and threonine residues with 
cysteines; iii) lanT, which encodes a transporter enzyme for export the lantibiotic; iv) 
lanP, the gene encoding the protease for the cleavage of the leader peptide; v) lanRK, 
which encodes a two-component regulatory system; vi) lanFEG, encoding a 
transporter enzyme responsible for the immunity of the producer bacteria to mature 
lantibiotic [13]. 
This are the most common genes in a general lantibiotic gene cluster. 
Proceeding from left to right on the cluster represented in Fig 15, the genes in 
cinnamycin gene cluster are the following. 
 
 
Fig15: Representation of the cinnamycin gene cluster 
 
 
cinorf3: encodes an N-terminal signal peptide. It shares 78% homology with a 
membrane protein of Streptomyces coelicolor [15] 
 
 
cinorf4: seems to encode a regulatory protein with a helix-turn-helix DNA-binding 
motif similar for the 67% to an S.coelicolor protein [15]. 
 
cinorf7: is a 360 bp long gene. It seems to encode the enzyme responsible to 
synthesize the lysinoalanine bridge, as reported in [12]. 
 
cinA: is the gene encoding the cinnamycin prepeptide. It has a length of 234 bp. 
 
cinM: encodes the modification enzyme cinM, member of LanM family, thus 
responsible both for the dehydratation and cyclization of Ser and Thr residues. This 
gene contains the rare leucine codon TTA, for this reason in this project the cinM gene 
was modified to replace this rare codon. The gene has a length of 3276 bp [16]. 
 
cinX: this gene has a length of 968 bp. It encodes the protein for the hydroxylation of 
Asp [12]. 
 
cinT and cinH: cinT share homology with a transporter membrane protein of ABC 
family transporter. CinH seems to be similar to a protein involved in drug efflux and 
resistance, suggesting that it could have a role in the immunologic system [13]. 
 
cinY: encodes a product that may possess an N-terminal signal peptide, suggesting 
that it may be exported. 
 
cinZ: has a length of 627 bp. The function in unknown. 
 
cinorf8: has a length of 420 bp and seems to be a member of the CoA-binding protein. 
[13] 
 
 
cinorf9: has a length of 321 bp. The encoded protein may have a possible N-terminal 
signal peptide suggesting that could be exported [13]. 
 
cinR and cinK: Encodes a two-component regulatory system and shares homology 
with two protein in the regulatory system of Bacillus subtilis [13]. 
 
cinorf10 and cinorf11: does not show significant similarity with other proteins. 
 
cinR1: encodes a protein involved in Streptomyces regulatory system. [13]. 
 
cinorf12, cinorf13 and cinorf14: does not show similarity with other proteins [13]. 
 
In conclusion, the genes involved in the modification and expression of cinnamycin 
are cinA, cinM, cinX and cinorf7. Thus these genes were the ones selected for the 
heterologous expression in E.coli described in chapter 3. 
 
2.2.2 Modification machinery of cinnamycin 
 
Only the genes cinM, cinX and cinorf7 encode a modification enzyme in the entire 
gene cluster of the lantibiotic cinnamycin. 
These modification enzymes act on the pre-peptide encoded by the gene cinA. 
As in others lantibiotics the modification enzymes recognize the target molecule 
thanks to the presence of a leader peptide. 
The cinnamycin leader peptide has a length of 59 a.a., whereas the core peptide is 
long 19 a.a. 
The cleavage of the leader peptide is necessary to obtain the active molecule after the 
modification of the core peptide. 
 
Mature cinnamycin has a globular structure, unlike the rod-like structure of nisin, and 
carries several kind of post-traslational modification. 
Cinnamycin belongs to class II lantibiotics: this means that the introduction of Lan 
and MeLan rings depends on a single LanM enzyme, CinM. 
Unlike nisin, the introduction of the thioether-bridge containing a.a is not the only 
modification. 
Cinnamycin harbour an erythro-3-hydroxy-L.aspartic acid resulting from the 
hydroxylation of L-aspartate by CinX [12]. 
The last modification in cinnamycin core peptide is the lysinoalanine bridge, carried 
out by enzyme Orf7. 
This modification is fundamental to confer antimicrobial activityto cinnamycin, 
because this bridge can bind the target of cinnamycin in the membrane of bacteria. 
The two modifications described above are illustrated in figure 16. 
(a) (b) 
 
Fig 16: Representation of lisynoalanine bridge (a) and of hydroxylated aspartic acid (b) 
 
 
The modification enzyme CinM requires the presence of a leader peptide to modify 
the substrate. 
 
This class LanM enzyme is responsible for the dehydratation of Ser and Thr residues 
in cinnamycin core peptide. 
In total four residues are modified, two serine at positions 4 and 6 and two threonine 
at positions 11 and 18. 
This process leads to the formation of two dehydroalanine resulting from dehydration 
of Ser residues, and two dehydrobutyrines, resulting from dehydration of Thr residues. 
LanM enzymes as CinM carry out also the cyclization of these dehydro-residues 
matching them with cysteine. 
Unlike the case of nisin, where the cyclization is driven by the single enzyme nisC, in 
cinnamycin the Lan and MeLan rings are generated in a bidirectional way, such that 
the MeLan rings are formed using cysteines that are located N-terminal to the 
dehydrobutyrines, and the Lan bridge is formed using a cysteine located C-terminal 
to dehydroalanine with which it reacts [12]. 
In total the action of CinM introduces one lanthionine ring and two methillanthionine 
rings, and also an additional dehydroalanine involved in lysinoalanine bridge 
formation. 
The action of CinM is summarized in the figure below. 
 
 
 
 
 
 
 
Fig 17: Schematic representation of the action of CinM. It is possible to note the different 
orientation of Lan and MeLan bridges. The link between the second Dha and the last lysine 
is the lysinoalanine bridge. 
 
 
Analysis on cyclase enzymes (ex. Subtilin SpaC and nisin nisC) dimostrated that this 
protein contains zinc. 
These results were confirmed from the anlaysis of the crystal structure of NisC. 
The zinc seems to be involved in the formation of thioether rings [17]]. 
LanM enzyme share sequence homology at the C-terminus with LanC cyclases, 
including two Cys and one His that coordinate the Zn2+ in LanC proteins. 
Thus, it was hypothesized that LanM cyclase domains might act through a similar 
zinc-involved mechanism. 
This hypothesis was confirmed with a spectrophotometric assay using metallochromic 
indicator [12]. 
The peculiarity of CinM to drive the formation of Lan and MeLan bridge in a 
bidirectional manner makes this enzyme interesting from the Synthetic Biology point 
of view, because it could be used to introduce Lan and MeLan ring in a different 
manner. 
 
CinX is the enzyme responsible for the hydroxylation of Asp in position 15 of core 
peptide. 
It was demonstrated [12] that the action of CinX can happen both after or before the 
formation of Lan and Melan rings. 
This means that there is not a specific order in the modification steps for cinnamycin. 
 
Furthermore, it was demonstrated that CinX does not need the presence of a leader 
peptide to carry out its action, unlike most lantibiotics modification enzymes. 
 
Orf7 is the protein encoded in the gene cinorf7. This small protein (13 kDa) carries 
out the formation of the lysinoalanine bridge, matching the last lysine of the core 
peptide with the dehydroalanine in position 4. 
Activity test for cinnamycin missing lysinoalanine bridge gives negative result, 
showing that this modification is fundamental in the antimicrobial activity. 
Therefore, in vitro modification of partially modified cinnamycin (modified by CinM 
and CinX) with Orf7 shows again negative result. 
Thus, this could mean that Orf7 requires the presence of the other modification 
enzymes to carry out its own function, and not only a dehydratated serines and a 
lysine. 
 
 
 
 
 
 
 
 
Fig 18: Schematic representation of the biosynthesis of cinnamycin by S.cinnamoneus. 
 
 
 
 
2.2.3 Mode of action of cinnamycin 
 
Unlike nisin and others class I lantibiotics, or class II lantibiotic mersacidin, 
cinnamycin does not target Lipid II, but interacts with membrane proteins such as 
phospholipase A2. 
Phospholipase A2 has a major role in the release ofarachidonic acid from 
phospholipids in the cell membranes. Further oxidative metabolism of free 
 
arachidonic acid leads to prostaglandins and leukotrienes. Several of these 
eicosanoids are potent mediators of diseases, such as inflammation and allergy [18]. 
In addition, A2 phospholipase is involved in atherosclerosis. 
Inhibition of the enzymatic activity of phospholipase A2 may therefore be 
therapeutically beneficial. 
Cinnamycin shows activity against Gram-positive bacteria as Clostridium botilinum 
and Mycobacterium [14]. 
This lantibiotic also causes the trans-bilayer phospholipid movement in the 
membrane of mammalian cells to access phosphotidylethanolamine (PE) residing 
predominantly in the inner side of the membrane [19]. 
PE is also a substrate for the phospholipase A2. 
The lantibiotic duramycin, a close structural analogus of cinnamycin, promotes 
chloride secretion in lung ephitelial cells by binding to PE. 
This secretion lead to a mucus clearance from the lung, as result this compound I is 
in phase II clinical trials for the treatment of cystic fibrosis [12]. 
For this reason cinnamycin has been suggested as an alternative treatment for 
atherosclerosis, because can inhibit phospholipase A2 by binding its substrate PE. 
 
 
 
 
 
CHAPTER 3: Material & Methods 
 
This research project can be divided in three modules. 
The first one involves the heterologous expression of cinnamycin in E. coli. 
Ti do that was necessary to introduce in the bacteria the gene encoding for the LanA 
peptide and the genes encoding for the modification enzymes. 
The peptide was expressed by this heterologous system, purified and its activity 
 
tested. 
The second module involves the modification of nisin fused with a chimeric leader 
peptide formed by the fusion of cinnamycin leader peptide and nisin leader peptide. 
Nisin was modified by nisin system (NisBC) and the leader peptide was cleaved by 
NisP. 
The aim of this module was to check if the presence of the cinnamycin leader 
peptide upstream nisin leader could affect nisin modification and activity. 
The last part of the project aimsto prove the modification of nisin by a single class 
LanM enzyme, CinM. 
Therefore, the modification of CinM on nisin was tested with the previous chimeric 
leader peptide. 
Figure 19 illustrates a summary of the project. 
 
 
Figure 19: Outline of the research project. 
 
 
3.1 Heterologous expression of cinnamycin in E. coli 
 
The heterologous expression of cinnamycin in E.coliinvolves several steps. 
Firstit was necessary to select the correct genes for the expression of the cinnamycin 
pre-peptide and for the expression of the modification enzymes. 
In particular it was necessary to  use a mutated variant of the structure gene cinA to 
bypass the absence of a dedicated protease for the cleavage of the leader peptide in 
cinnamycin gene cluster. 
Once the genes were selected, the next step was the cloning of these genes in 
plasmid vectors. 
Then the plasmid carrying the genes were introduced in the bacteria by 
electroporation. 
After that, fresh-transformed cells were used to start a culture and obtain the 
expression of the cinnamycin. 
After that, the cells werelysated and the peptide molecules purified. 
A digestion step with protease LysC was necessary for the cleavage of the leader 
peptide. 
Finally, the activity of fully modified cinnamycin was tested against Gram-positive 
bacteria B.subtilis and M.luteus. 
 
3.1.1 Cloning of genes involved in expression and modification 
 
To obtain cinnamycin expression are necessary the structure gene cinA, encoding the 
cinnamycin pre-petide, and the genes encoding the modification enzymes CinM, 
CinX and Orf7. 
The aim of these cloning steps is to obtain a pACYC plasmid that harbors the two 
modification enzymes orf7 and cinX, and a pRSF plasmid with cinA and cinM. 
 
The genes used for this project are not the wild type genes, but are modified to 
increase the expression level for E.coli. 
This genes were provided by Lanthiopharma, a company which collaborate with 
Molgen research group of the Groningen University. 
In particular,cinMwas modified to replace the rare codon “TTA” that encodes for 
leucine with a more common codon. In this way the expression of CinM is 
optimized for an heterologous producer. 
The ribosome binding site (RBS) or orf7was removedbecause an RBS was already 
present in the first cloning site of pACYC plasmid, in this way a double RBS 
situation was prevented. 
The modified Orf7 is called Orf7b. 
The most important modification involves the structure gene cinA. This gene 
encodes for the cinnamycin pre-peptide, formed by cinnamycin leader peptide and 
core peptide. 
As reported in chapter 2 there is not a specific protease for the cleavage of the leader 
peptide in cinnamycin gene cluster. It seems that in the natural producer strain this is 
obtained by peptidase of the general secretory pathway Sec. 
In E.colithe cleavage cannot be obtained in this way, so itis necessary to use a 
specific protease. 
For this reason,cinA was mutated to replace the alanine at the last position of the 
leader peptide (position -1) with a lysine. After this mutation the gene is named 
cinA(A-1K). 
In this way is possible to obtain the cleavage by protease LysC that can break the 
peptide bond at the C-terminal side of lysine. 
Only two lysine are present In cinnamycin sequence after this mutation, one at the 
last position of the leader peptide and the second at the last position of the core 
peptide. 
 
Therefore, using LysC lead to a single cut that allow the separation of the leader 
peptide from the core peptide. 
The genes were cloned into a pRSF and a pACYC plasmid. 
Both these plasmids possess two separate cloning site, each one controlled by an 
IPTG inducible promoter. 
For this reason a gene encoding lactose inhibitor is present in both plasmids under 
the regulation of a constitutive promoter. 
Kanamycin resistance gene is present in pRSF plasmid, whereas a gene encoding for 
chloramphenicol resistance is present in pACYC. A constitutive promoter regulates 
these two genes. 
These two plasmids possess the same origin of replication (ori), this mean the will 
be present in the same number inside the host. 
The first cloning site of the pRF plasmid possess a his-tag sequence. 
Therefore, cloning of a gene downstream this sequence to obtain the protein 
expressed in the gene with a sequence of histidine at N-teeminal side is possible. 
In this case the gene in the first cloning site of the pRSF plasmid was cinA(A-1K). 
The his-tag (formed by six histidine residues) is necessary to detect the expression 
of the pre-peptide and for its purification by affinity chromatography. 
The structure of the two plasmids used in this project are reported tIn the figure 
below. 
 
 
 
 
Fig 20: Structure of pACYC and pRSF plasmids 
 
The final expression system consist in a pACYC plasmid carrying in the first 
cloning site orf7b and in the second cloning site cinX (pACYC orf7b-cinX), and a 
pRSF plasmid carrying cinA(A-1K) in the first cloning site and cinM in the second 
(pRSF cinA(A-1K)-cinM). 
The project started from a pACYC orf7b and a pRSF cinA(A-1K) already built by 
Lanthiopharma. 
To obtain the final expression system the following steps were performed: 
 PCR to amplify the genes cinX and cinM 
 
 Digestion 
 Ligation 
 Transformation 
 Colony PCR 
 Sequencing 
The first step was to amplify the gene by PCR. 
To do that it was necessary to design primers to amplify cinX, whereas for cinM case 
was possible to use the general primers for pACYC plasmid. 
In fact, a cinM gene was contained in the second cloning site of a pACYC 
plasmid,thus was possible to amplify it using the couple of primers pACYC 2nd-Fw 
and pACYC 2nd-RV, that allow to amplify the second cloning site of the plasmid 
when used together in a PCR step. (Primers sequences are reported in supporting 
information section) [SI 1]. 
CinX was contained in a pET plasmid, so it was necessary to design the correct 
primers to amplify the gene. 
The primers were designed using the software Clone Manager. 
PCR reaction was carried out using phusion polymerase enzyme by Thermo 
scientific, and result analyzed by electrophoresis. 
According to Clone Manager, PCR product for cinX case is 1030 bp, whereas for 
cinM case is 3456 bp. 
These results are reported below. 
 
 
 
Fig 21: Analysis by electrophoresis of (a) PCR products for cinX case, (b) PCR products 
for cinM case. 
 
 
The PCR product contains the gene sequence plus additional DNA, whichharbors 
restriction sites for digestion enzymes. 
Using the correct combination of digestions enzyme it is possible to  introduce the 
gene sequence into the plasmid. 
For cinM PCR product was possible to cut the DNA sequence by enzymes NdeI and 
KpnI (the same enzyme cut the pRSF plasmid). 
This leaded to an open plasmid that can harbor the gene in its second cloning site. 
 
 
Fig 22: cinM PCR product. The restriction sites are shown. The upstream and downstream 
enzymes NdeI and KpnI were used to cut this sequence. 
 
For the cinX case the restriction enzymes NdeI and XhoI were used. 
The same enzymes were used to cut the pACYC plasmid. 
For digestion steps were used FastDigest enzymes by ThermoScientific. 
The results were analyzed by electrophoresis, and the digestion reactions were then 
purified to separate the DNA sequences and perform the ligation step. 
In the ligation step opened plasmids and gene sequences were mixed making the 
correct couples (pACYC orf7b + cinX, pRSF cinA(A-1K) + cinM), an then ligation 
reaction was performed overnight at 4°C using T4 DNA ligase enzyme. 
Ligation products were then used for transformation. 
The plasmids were separately introduced in E.coliTOP10 strain by electroporation, 
and plated in Petri dishes with LB (Luria-Bertani) medium with the correct 
antibiotic. 
The plates were left in incubation overnight at 37°C and the day after colonies were 
used for colony PCR (CPCR) step. 
 
Colony PCR (CPCR) technique allow to check if cells of a certain colony possess 
the plasmid with the insert in it. In this way is possible to exclude cells with the 
plasmid that do not carry the insert. 
CPCR is similar to classic PCR with the difference that instead of DNA template is 
used a colony. 
Therefore is necessary a longer step at 98 °C to break the cell wall and make 
available the DNA to primers and polymerase. 
Using the correct couple of primers is possible amplify a region of the plasmid 
contained in the cells. 
CPCR allow to amplify only fragment shorter than 1000 bp. 
This is not a problem for the cinX case, because cinX is 980 bp, so it was possible 
used the previous primers. 
For cinM case was necessary design two specific primers called cinM-Fw and cinM-
Rv. 
Coupling this two primers with pRSF-2nd-Rv and pRSF 2nd-Fw was possible amplify 
the 3’ and 5’ part of cinM. 
The products using these primers couples are around 300 bp. 
CPCR results are available in supporting information [SI 2]. 
Using the colonies that gave good result in the CPCR step a culture was started and 
cells left growth overnight to amplify the plasmids. 
Then the cells was treated to obtain plasmids that were sent to sequencing. 
Sequencing operation was necessary to confirm the correct nucleotidic sequence of 
the genes carried on the plasmids. 
Once the sequencing confirmed the correctness of the gene sequences, plasmids 
were used together in a transformation step, using E.coli strain BL21. 
This strain is optimized for the expression of the genes carried in the plasmids. 
After this transformation the cells contains the entire heterologous expression 
system. 
 
The expression system is illustrated in the figure below 
 
 
Fig 23: Heterologous expression system for cinnamycin. 
 
3.1.2 Expression and detection of the cinnamycin peptide. 
 
Cells containing the two-plasmid system were inoculated in 2 l of LB medium with 
5 µg/ml of chloramphenicol and 25 µg/ml of kanamycin. 
Cells were grown at 37°C until an OD value between 0.6-0.8 at 600nm was reached. 
At this point 1mM IPTG was added to induce the transcription of the genes carried 
on the two plasmids, this leaded to the expression of cinnamycin pre-peptide and 
modification enzymes. 
Culture was left in incubation overnight at room temperature with shacking. 
 
As shown in the figure above, E.coli heterologous expression system for cinnamycin 
lacks of a transportation system to export the peptide in the extracellular 
environment. 
Therefore, to break the cells and analyze the cell lysate was necessary to detect the 
presence of the molecule. 
In addition, from literature is known that overexpressed protein could be stored in 
inclusion bodies, protein aggregate made by the cells. 
First, the cellular pellet was harvested and resuspended in a phosphate buffer called 
Start Buffer [SI 3]. 
Then the cells were broken by sonication and centrifuged [27]. 
The supernatant, that is the cell lysate, was kept and named “1st Start Buffer”. 
The pellet was then resuspended again in Start Buffer and centrifuged. 
This step was necessary to remove all the residues of medium from the pellet. 
Then the pellet, that contains inclusion bodies, was treated with an8M Urea 
Denaturing Buffer [SI 3]. 
Urea is a strong denaturing agent that allow to solubilize the inclusion bodies. 
The sample was centrifuged again and the supernatant kept and named “Inclusion 
Bodies”. 
Samples were then analyzed by SDS-PAGE and Western blot to check the 
expression of modification enzymes and cinnamycin. 
SDS-PAGE confirmed the expression of all the modification enzymes, whereas 
Western Blot with anti-his-tag antibodies confirmed the presence of cinnamycin  
pre-peptide [SI 4]. 
After these steps was necessary purify the peptide by Affinity Chromatography, 
before check the activity of cinnamycin. 
Affinity Chromatogpahy allow the isolation of the peptide exploiting the presence of 
the histidine contained in his-tag sequence. 
 
These residues can bind the nickel contained in a column in which the sample is 
load, leading to the separation of the target molecule from the others compounds. 
The target molecule is then eluted using an imidazole containing buffer that can bind 
hisitidine and therefore drag the molecule out of the column. 
Affinity Chromatography was performed by NGC machine by BioRad using a GE 
HealthCare nickel coloumn. 
Buffers used for this step are described in [SI 5] . 
NGC machine has a spectrophotometer at the exit of the column that allow 
checkingof the elution of compounds. 
The profile for the inculsion bodies sample is shown below. 
 
 
 
Fig 24: NGC Affinithy Chromatography profile for inclusion bodies sample. The peak 
labeled with a red circle represent the elution of the target molecule. 
 
The blue line represent the absorbance level at 280 nm. 
At this wavelength tryptophan, show a high absorbance. 
Checking the leader peptide sequence a tryptophan residue was found. 
 
This mean that the peak labeled with the red circle represent the elution of the target 
molecule. 
The result was further confirmed by western blot performed for the elution fractions 
on which the peak was detected. 
As negative control, Affinity Chromatography was performed also for sample after 
inclusion bodies treatment obtained from a culture that was not induced by IPTG. 
The profile for this sample [SI 6] did not show any peak, meaning that there is no 
production of cinnamycin. 
Western blot confirm this result. 
This mean that IPTG inducible promoters tightly regulate this heterologous 
expression system. 
 
3.1.3 Purification and mass spectrometry analysis 
 
After affinity chromatography, the sample was analyzed by mass spectrometry. 
Mass spectrometry allow detection of the molecular weights of the compounds of a 
solution. 
In this case was used to detect if the peptide is actually present by checking the 
know molecular weight. 
Modified/unmodified cinnamycin with the leader peptide and his-tag still attached 
has a molecular weight of approx. 9800 Da. 
Unfortunately, for this sample the MALDI-ToF MS (Matrix Assisted Laser 
Desorption Ionization-Time of Flight Mass Spectrometry) analysis did not show 
clear result. 
A non-clear peak was detected around 9600-10100 Da, highlighting the need of 
further purification. 
 
 
 
 
Figure 25: MALDI-Tof profile of inclusion bodies sample after NGC. The red circle 
represent the area of interest in which the peak representing the cinamycin peptide should 
be present. The indication of the theoretical molecular weight of the target molecule is 
reported. 
 
Therefore, to obtain a pure peptide a HPLC was performed. 
HPLC (High Performance Liquid Chromatography)allows to separate the several 
compounds of a solution exploiting the different affinity of each compounds 
between a “stationary solution” and a “mobile solution”. 
It relies on pumps to pass a pressurized liquid solution containing the sample 
mixture through a column.Each component in the sample interacts slightly 
differently with an elution solution that flows through the column, causing different 
flow rates for the different components and leading to the separation of the 
components as they flow out the column. 
A spectrophotometer positioned outside the column consents to detect the eluted 
compounds. 
 
After this step several samples, each representing the elution of a different 
compound, were obtained 
The HPLC output profile for the previous sample is reported. 
 
Fig 26: HPLC profile. Each peak represent the elution of a compound of the sample 
solution. The wave length used for the detection are reported. Each peak was labeled with 
a number. 
 
In total eight samples were obtained after this purification step. 
To check which of these samples contains the target molecule an additional 
MALDI-ToF analysis was performed. 
Analysis of the samples number eight shown a very clear peak, even if the detected 
molecular weight did not fit with the theoretical molecular weight of modified 
cinnamycin with leader and his-tag, but it is smaller. 
This could mean that also the leader peptide is dehydrated.  
 
 
Figure 27: MALDI-ToF profile for sample number 8 obtained from HPLC. 
The detected molecular weight and the theoretical molecular weight of the target molecule 
without modification are indicated. 
 
The same sample was also digested by protease LysC, overnight at 37°C. 
Before doing that it was necessary to lyophilize the sample and resuspend the 
powder in Tris-HCl Buffer. 
After digestion by LysC the sample was again analyzed by MALDI-ToF. 
This time the peak, representing only the modified core peptide fitted with the 
theoretical molecular weight. 
The modification necessary to obtain cinnamycin that modify the molecular weight 
are four dehydration and ahydroxylation. 
To consider a dehydration is necessary subtract from the molecular weight of the 
core peptide (2097,3 Da) the molecular weight of an oxygen (15.99 Da) and two 
hydrogen (1 Da). 
The hydroxylation is taken into account by adding the molecular weight of an 
oxygen and of and hydrogen. 
 
The molecular weight of fully modified cinnamycin is 2041,3 Da. 
This result show that the molecule contained in the sample is probably fully 
modified cinnamycin. 
 
 
Figure 28: MALDI-ToF analysis after digestion by LysC. The theoretical molecular weight 
of fully modified cinnamycin and the detected molecular weight are reported. 
Also the modification on the copre peptide are reported. CP: core peptide   
 
To test this, an activity test was performed. 
In the activity test an indicator strain (the strain that represent the target for the 
molecule) is add to a mixture of LB and agar. 
The concentration of agar shouldn’t be too high to allow the diffusion of the 
antimicrobial molecule. 
The sample was spotted on the plate, with higher and lower concentration. 
In addition, pure nisin was used as positive control. 
 
The antimicrobial activity lead to area in which the growth of the indicator strain is 
inhibit, meaning that the molecule possess activity against the indicator strain. 
This is the case of cinnamycin, which shown activity against Bacillus subtilis and 
Micrococcus luteusas reported in the figure below. 
In addition, an activity test with samples before the HPLC treatment was performed 
[SI 7]. 
The result was negative and this confirms that the molecule do not have activity 
before the cleavage of the leader peptide, as expected. 
 
Figure 29: Activity test for heterologous expressed cinnamycin. 
 
All this results show that cinnamycin and its modification enzymes can be expressed 
in E. coliand also that production of active cinnamycin by heterologous producer is 
possible. 
In particular it was confirmed that the modification enzyme CinM can work in 
E.coli, and for that reason was tested for modification of nisin. 
 
 
3.2 Test of nisin modification system in E.coli on nisin with chimeric 
leader peptide 
 
The second part of the project involves the modification of nisin, modified to obtain 
a chimeric leader peptide formed by the fusion of cinnamycin leader and nisin 
leader, by the nisin modification enzymes NisB and NisC. 
The aim of this experiment is to check if the presence of the cinnamycin leader 
peptide could affect the nisin modification, activity or expression in E.coli. 
Once confirmed that the presence of the cinnamycin leader does not affect nisin 
production system the next step was tested the modification of nisin by CinM, as 
described in paragraph 3.3. 
 
3.2.1 Design and cloning of the synthetic design encoding nisin with chimeric 
leader peptide. 
 
The first step was the design of the synthetic gene encoding nisin with a chimeric 
leader peptide made by the fusion of cinnamycin leader and nisin leader peptide. 
The synthetic gene was designed by Clone Manager, and includes the following 
modules: i) a his-tag region necessary for detection and purification of the peptidic 
molecule; ii) the DNA sequence encoding the leader peptide of cinnamycin; iii) the 
DNA sequence encoding for nisin leader peptide; iv) sequence encoding nisin core 
peptide. 
In addition, upstream and downstream of this gene were positioned the restriction 
site for NcoI and HndIII restriction ezymes. 
In total, the sequence is 419 bp long. 
A representation of the modules of the synthetic gene is reported below 
 
 
 
 
Fig 30: schematic representation of the synthetic gene 
 
This gene was cloned in the first cloning site of a pACYC plasmid, therefore its 
expression was regulated by an IPTG inducible promoter. 
The cloning of this plasmid involved the same steps of the plasmids construction in 
the previous paragraph: 
 PCR to amplify the synthetic gene using two designed primers [SI 1 ] 
 Digestion of the synthetic gene and of the empty pACYC plasmid by NcoI 
and HindIII 
 Ligation 
 Transformation in E.coliTOP10 
 CPCR and Sequencing 
 
The other part of the expression system is constituted by a pBAD plasmid carryng 
the two genes nisB and nisC, in two separate cloning sites. 
This plasmid possess the resistance gene against ampicillin (Amp), and two 
arabinose inducible promoters. 
The two enzymes encoded in this plasmid have the task to modify the peptide 
encoded in the synthetic gene to obtain active nisin. 
 
 
 
Fig 31: Representation of the two-plasmid system for the modification of nisin with 
chimeric peptide. 
 
3.2.2 Expression and activity test 
 
The two plasmids were introduced inside the cells (E.coli BL21) by electroporation. 
Transformed cells were used to inoculate a culture of 200 ml of LB with addition of 
chloramphenicol 5 µg/ml and ampicillin 100 µg/ml. 
Cells were left grown until the OD measured at 600 nm reached a value of 0.6-0.8. 
Then transcription was induced by addition of 1mM IPTG and 0.05% arabinose. 
Culture was left in incubation overnight at room temperature with shacking. 
As for the case of cinnamycin expression system, in this expression system there is 
not a transportator for the peptide, so it was necessary to break the cells and analyze 
cells lysate and inclusion bodies. 
 
Cells were treated as described before and samples from cell lysate and inclusion 
bodies were analyze by SDS-PAGE and Western blot. 
The peptide produced by this system has a molecular weight of approx. 13 kDa. 
An intense band was detected in the SDS-PAGE for the inclusion bodies sample. 
 
 
Fig 32: SDS-PAGE for cell lysate and inclusion bodies samples. 
 
It is possible to obtain the cleavage of the leader peptide by NisP enzyme for this 
peptide, named H-CinL-nisA. 
So the activity can be checked without the previous purification steps. 
To do that it was necessary to perform an activity test with a particular indicator 
strain. 
The indicator strain is L.lactis nz9000 modified with the introduction of a plasmid 
encoding NisP and a plasmid encoding the regulatory nisin enzymes NisK and NisR. 
 
A constitutive promoter regulates the transcription of these two genes, whereas a 
nisin inducible promoter regulates the transcription of NisP. 
This promoter is regulated by the action of NisK and NisR. 
So in the preparation of the mixture for the activity test in addition to M17 (medium 
necessary for L.lactis growth) agar and strain, also a small amount of nisin was 
added. 
This small amount of nisin cannot kill the indicator strain because is too low, but is 
enough to start the signal cascade that lead to the activation of nisP transcription by 
NisK and NisR. 
Therefore, the indicator strain on the plate is the producer of NisP necessary for the 
cleavage of the chimeric leader peptide. 
If nisin is correctly modified, area in which the growth is inhibit appears. 
The samples obtained by treatment of cell lysate and incusion bodies were spotted 
on the plate and activity zone were detected especially for inclusion bodies sample. 
 
 
 
Fig 33: Activity test for H-CinL-nisA samples. 1 and 2 are samples from first and second 
wash of cell lysate with Start Buffer. 3 is the sample from incusion bodies. 
4 and 5 are negative control (cells transformed with empty plasmid). 6 is the positive 
control necessary to check the correct cleavage of the leader (is modified nisin with 
original leader peptide). 7 is pure nisin. 
 
3.2.3 Purification and mass spectrometry analysis 
 
Inclusion bodies sample was then further purified by affinity chromatography and 
HPLC [SI 9-10]. 
After this two purification steps the activity test was performed again, and the 
sample obtained from elution peak number 5 of previous HPLC showed activity. 
 
Also sample from peak number 6 showed weak activity. 
 
 
Fig 34: activity test after HPLC purification step. 1,2,5,6 are the samples obtained from 
HPLC. 3 represent the negative control. 4 is the positive control and 7 is pure nisin. 
 
Sample number 5 was then analyzed by MALDI-ToF. 
The result is a clear peak at 13585 Da. 
According to Clone Manager, the theoretical molecular weight of H-CinL-nisA 
without modification is 13740 Da. 
In nisin modification eight dehydration are carried out, this means that the 
theoretical molecular weight of the fully modified peptide is 13596,38 Da, close to 
the one detected. 
 
 
 
Fig 35: MALDI-ToF analysis of H-CinL-nisA. 
 
The results proved that the expression of nisin with chimeric leader peptide is 
possible. 
Therefore, the modification and activity of nisin modified by NisB and NisCwas 
also proved. 
In addition, the results proved that the presence of the cinnamycin leader peptide 
does not affect the nisin production, modification and activity. 
Exploiting the presence of the cinnamycin leader peptide is then possible to try to 
modify nisin by the LanM enzyme CinM of cinnamycin modification machinery. 
 
3.3 Modification of nisin with chimeric leader peptide by CinM 
 
The results reported in the previous paragraphs open the way to the modification of 
nisin by modification enzyme CinM, exploiting the presence of the cinnamycin 
leader peptide in the chimeric leader peptide upstream nisin core peptide. 
Theoretically, CinM should recognize the cinnamycin leader peptide and then 
modify nisin core peptide. 
 
Belonging to class LanM modification enzymes, CinM carry out both dehydration 
and cyclization on nisin, leading to the production of mature and active nisin. 
To test this hypothesis the previous synthetic gene and cinM were cloned into a 
pACYC plasmid. 
Unlike the previous case, this system is formed by only one plasmid as illustrated in 
the figure below. 
 
 
Fig 36: Chimeric leader-peptide nisin modification system. 
 
Being a one-plasmid system the main differences with the previous nisin expression 
system are that is necessary add only chloramphenicol during the cells growth and 
IPTG for the induction. 
Basically the same steps used for nisin modification by NisB and NisC were 
followed. 
All the steps are summarized in the next figure. 
 
 
 
Figure 37: Steps involved to test nisin modification by CinM. 
 
Weak activity was confirmed for inclusion bodies sample by activity test against 
L.lactis nz9000 expressing NisP. 
This sample was then purified by affinity chromatography and HPLC. 
HPLC result show the presence of a clear elution peak. 
The elution fraction referred to this peak was then tested by activity test. 
Both the HPLC profile and activity test are reported below. 
For activity test was checked also if the sample has activity with the leader peptide. 
To do that an activity test against L.lactis without NisP expression system was 
performed. 
 
 
 
Fig 38: HPLC profile of inclusion bodies sample. Labeled peak represent the putative nisin 
modified by CinM with the leader peptide still attached. 
 
 
 
Figure 39: Activity test against L.lactis nz9000 with or without NisP expression of H-cinL-
nisA +CinM 
1: cell lysate sample. 2: inclusion bodies sample. 3: sample obtained after HPLC. 
4: nisin with chimeric leader modified by nisin system. 5: nsin with natural leader 
PC: positive control (pure nisin) 
 
 
From activity test it is possible to see weak but clear activity in sample 2 and 3. 
This means that CinM can modify nisin if this one is fused with a chimeric leader 
peptide containing cinnamycin leader. 
The result was confirmed also by MALDI-ToF analysis for sample 3 before 
cleavage of the leader pre-peptide. 
The peak size fits with the peak size detected for modification of H-CinL-nisA by 
nisin system. 
These result seems confirm that CinM and combination of NisB and NisC carry out 
the sames modification on nisin, as expected. 
 
Figure 40: MALDI-ToF data for H-CinL-nisA modified by CinM. The detected molecular 
weight is reported. The others two peaks labeled by +2H and +3H seems to be the target 
molecule ionizied two and three times respectively  
 
These results prove also that itis possible to use a modular schematization and 
conception for use of lantibiotics and modification enzymes, confirming that a 
Synthetic Biology approach seems to be a valid strategy in the design of novel 
lantibiotics. 
 
 
 
 
 
  
 
CHAPTER 4: Results and Discussion 
 
Heterologous expression system for cinnamycin was achieved by introduction of two 
plasmids, pACYC and pRSF, in E.coli. 
The first one carries the two modification enzyems orf7b, responsible for 
lysinoalanine formation, and cinX necessary for hydroxylation. 
The pRSF plasmid harbors the structure gene cinA(A-1K) that encodes cynnamycin 
pre-peptide, and cinM that encodes a class LanM enzyme responsible for both 
dehydration and cyclization. 
The obtained results proved that the heterologous expression system allow the 
expression of cinnamycin pre-peptide and of all the modification enzymes. 
This was proved by SDS-PAGE and Western Blot. 
To check the activity of cinnamycin was necessary to  cleave the leader peptide by 
protease LysC. 
To do that affinity chromatography and HPLC were performed to purify the target 
molecule. 
MALDI-ToF analysis confirms the cleavage of the leader peptide by LysC. 
In addition, mass spectrometry analysis allowed the detection of a product with 
molecular weight very close to the theoretical molecular weight of fully modified 
cinnamycin. 
Finally, the activity of heterologous expressed cinnamycin was confirmed by activity 
test againstBacillus subtilis and Micrococcus luteus. 
To obtain enough active product it was necessary to start with a culture volume of 2 
L. 
Attempt to obtain active compound starting with lower volume gave negative results. 
This means that the heterologous system has a low efficiency. 
 
In addition, the concentration necessary to obtain a positive result on the activity test 
is unknown. 
To overcome the low efficiency of the expression system it is necessary to check all 
the expression and purification steps, to find the better conditions. 
For example, the desalting step necessary to remove imidazole used during affinity 
chromatography should be performed as soon as possible to prevent peptide 
precipitation that lead to a loss of product. 
Also, to check the minimum amount of active product necessary to show activity in 
the activity test is necessary. 
To do that it is possible to compare the effect of different aliquots of heterologous 
expressed protein with the effect of authentic cinnamycin at known concentrations. 
The second part of the work involved the heterologous expression of nisin with a 
chimeric leader peptide formed by fusion of cinnamycin and nisin leader peptide, and 
the test of nisin modification enzymes on this molecule. 
The results show that the expression of the chimeric molecule is possible and also its 
modification. 
This means that the presence of cinnamycin leader peptide upstream nisin leader 
peptide do not affect the recognition by NisB and NisC of nisin leader peptide neither 
nisin modification. 
The modifications was confirmed by activity test and partially by MALDI-ToF. 
The activity detected was very clear, and comparable to normal nisin. 
In the end, modification of the previous chimeric molecule by CinM enzyme was 
attempted. 
The heterologous expression of cinnamycin confirmed that CinM can be expressed 
and can work in E.coli. 
The idea was to exploiting the presence of cinnamycin leader peptide to obtain nisin 
modified by a single class LanM enzyme. 
 
Activity was detected and confirmed by MALDI-ToF analysis, that gave a similar 
result to the mass spectorometry analysis of the same molecule modified by nisin 
modification enzymes. 
This means that the two system provide the same modification on the molecule. 
Therefore, CinM can modify nisin. 
The detected activity was very weak if compared to normal nisin and nisin with 
chimeric leader peptide. 
Expression levels for the chimeric molecule are very similar in both cases, meaning 
that the presence/absence of CinM expression do not affect the expression of the 
peptide. 
Therefore seems that CinM action on this molecule is not so efficient. 
Anyway, the expression system is formed by just one plasmid, unlike the two previous 
two-plasmid systems. 
This leads to a lower metabolic load for the bacteria. 
A way to increase the activity of CinM on  nisin core peptide region is to optimize the 
chimeric leader peptide, for example with a shorter nisin leader. 
This should provide an increase on the efficiency of CinM because there is less space 
between the cinnamycin leader and the core peptide region. 
Anyway the cleavage of the leader peptide should be still possible using NisP. 
This hypothesis has to be proved experimentally. 
Even if this system have to be optimized to increase the production efficiency and 
activity of the product, the results are promising and lead to new challenges. 
CinM, showed that in cinnamycincan lead to the formation of Lan and MeLan bridges 
opposite oriented with respect to the bridges present on nisin. 
So, it would be interesting to check if nisin modified by CinM harbor the “inverted” 
bridges and what are the implications. 
In addition, CinM activity should be tested on others lantibiotic using a similar 
chimeric leader method. 
 
Finally, from cinnamycin modification system analysis seems that Orf7 can work only 
with the simultaneous presence of CinM. 
Therefore, if CinM can work on nisin is also possible try to introduce the lysinoalanine 
bridge on nisin obtaining a new to nature molecule. 
Another way is to design a fused core peptide made by the region that harbor the rings 
A, B and C of nisin and a designed tail. 
The rings can be obtained using CinM whereas in the deigned tail can be introduced 
a lysinoalanine bridge by Orf7. 
This kind of hypothetical new to nature molecule is shown below. 
 
 
Figure 41: Hypothetical lantibiotic that can be produce by a synthetic biology approach 
using CinM and Orf7. 
. 
 
 
 
 
 
 
 
 
 
 
CONCLUSIONS 
 
Lantibiotic peptides possess strong activity against a wide range of Gram-positive and 
Gram-negative bacteria, and represent a potential solution to fight the growing 
problem of multi-drugs resistant pathogens. 
Antimicrobial activity is due to post-translational modifications, that changes 
structure and proprieties of the peptide. 
The modifications are carried out by specific modification enzymes that recognize the 
leader sequence and act on the core peptide. 
Using a Synthetic Biology approach that involves the combination of different 
substrates and different modification enzymes it is possible to obtain new to nature 
lantibiotic. 
Therefore, the final goal is to obtain a plug and play system that can be used to select 
different sets of modification enzymes to work on diverse, specifically designed 
substrates, with the aim to obtain new to nature molecules with antimicrobial activity 
and/or new physicochemical proprieties. 
The intention was to enlarge the “library” of available modification enzymes that can 
be used in the plug and play system, by adding CinM, the enzyme responsible for 
lanthionine and methylanthionine formation in cinnamycin. 
Therefore, the aim of this research was to prove the modification of nisin by the single 
class LanM enzyme, CinM belonging to cinnamycin modification machinery. 
To do that, it was necessary to implement a heterologous expression system formed 
by two plasmids carrying the genes for modification enzymes and for cinnamycin pre-
peptide. 
The gene encoding for cinnamycin peptide was modified by substitution of alanine at 
the last position of leader peptide with a lysine. 
 
This was necessary to obtain the cleavage of the leader peptide by protease LysC, 
bypassing the problem of absence of dedicated protease in the heterologous system 
for this aim. 
MALDI-ToF and activity test confirmed the presence and activity of fully modified 
cinnamycin after the cleavage, proving that the heterologous system works well. 
This result proved the possibility of expression and modification of cinnamycin by 
heterologous host, and also that cinM can be produced and works in E.coli as well as 
the others cinnamycin modification enzymes. 
To obtain the modification of nisin by CinM, was necessary design a specific peptide, 
composed by a chimeric leader sequence obtained by fusion of cinnamycin leader and 
nisin leader upstream nisin core peptide. 
The idea was that CinM could recognize the cinnamycin leader and then modify nisin. 
Before proving that, it was necessary to check if the presence of cinnamycin leader 
affected the production and activity of nisin. 
The synthetic gene encoding for the chimeric molecule was designed by Clone 
Manager and then introduced in E. coli. 
Also a pBAD plasmid carrying the nisin modification enzymes NisB and NisC was 
introduced. 
Expression of the chimeric molecule was proven by SDS-PAGE and Western blot. 
MALDI-ToF and activity test confirm that active and fully modified nisin can be 
produced and modified by NisB and NisC even with the presence of cinnamycin 
leader peptide. 
Once proven that cinnamycin leader does not affect nisin modification, the same 
molecule was modified by CinM. 
For this aim, a single plasmid system was built and introduced in E. coli. 
As before, SDS-PAGE and Western Blot proved peptide presence. 
MALDI-ToF result was same as the previous case, meaning that CinM and 
combination of NisB and NisC carry out the same modification on nisin. 
 
Finally, activity of nisin modified by CinM was detected by activity test. 
The activity is weaker than natural nisin or chimeric nisin modified by nisin system, 
meaning that the efficiency of nisin modification by CinM is low. 
For that reason, is necessary optimize the modification condition, for example 
reducing the nisn leader length. 
In this way there is less space between cinnamycin leader and nisin core peptide. 
Anyway, even if the activity is not strong, modification of nisin by CinM was proved. 
This open the way to others possible experiments. 
For example, test CinM on others lantibiotics, or check if the orientation of Lan and 
MeLan bridges introduced by cinM on nisin is same as natural nisin or are opposite 
oriented. 
Furthermore, from literature is known that Orf7, the enzyme responsible for 
lysinoalanine formation, can work only with the presence of CinM. 
So, is now possible try to introduce the lysinoalanine bridge on nisin, obtaining a  
hyper-modified molecule. 
In conclusion, lantibiotics represent a potential solution to fight multi-drugs resistant 
pathogens. 
Synthetic Biology seems a promising way to obtain designed and new-to nature 
lantibiotics, with desired proprieties and activity. 
However, to obtain that is necessary standardized and master the behavior of 
modification enzymes and peptides. 
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SUPPORTING INFORMATION 
 
pRSF 1st-Fw: TCACCACCCTGAATTGACTC 
pRSF 1st-Rv: GGCCGTGTACAATACGATTACTTTC 
pRSF 2nd -Fw: GTACACGGCCGCATAATC 
pRSF 2nd-Rw: TAAGCTGCGCTAGTAGAC 
 
pACYC 1st-Fw: TCTCCCTTATGCGACTCCTG 
pACYC 1st-Rv: CGGCCGTGTACAATACGATTACTTTC 
pACYC 2nd-Fw: GTACACGGCCGCATAATC 
pACYC 2nd-RV: TAAGCTGCGCTAGTAGAC 
CinX-Fw: ATCCGGCTGCTAACAAAG 
CinX-Rv: CTTTCGCTCGAGTTAACC 
CinM-Fw: GACTGATGATCGGCATCTCC 
CinM-Rv: GCGATTCCTGGTGGAACTTG 
H-CinL-nisA Fw: ATCATACCATGGGCAGCAGCCATC 
H-CinL-nisA Rv: ATCATTCGGTACCAAGCTTATTTGC 
 
SI 1: Primers List 
 
 
 
SI 2: 1)pRSF cinA(A-1K)-cinM CPCR; Primers pRSF 2nd –Fw CinM-Rv (342 bp) 
2) pACYC orf7b-cinX CPCR; Primers pACYC 2nd-Fw pACYC 2nd-Rv (1161 bp) 
 
 
Start Buffer: 
20 mM NaH2PO4 
500mM NaCl 
0.5 mM imidazole 
20% glycerol 
pH 7.5 
 
 
Denaturing Buffer: 
100mM NaH2PO4 
10mM Tris 
8M Urea 
pH 8.0 
 
SI 3: Buffers list for lysation of cells and denaturation of inclusion bodies 
 
 
SI 4: SDS-PAGE and Western Blot. On the SDS-PAGE picture are indicated the 
modification enzymes. In western blot image band representing cinnamycin is 
highlighted 
 
Equilibration buffer: 
20 mM sodium phosphate,  
0.5 M NaCl, pH 7.4  
 
Wash buffer:  
20 mM sodium phosphate 
 0.5 M NaCl 
0 to 30 mM imidazole 
pH 7.4  
 
 
Elution buffer:  
20 mM sodium phosphate 
0.5 M NaCl 
500 mM to 1 M imidazole 
pH 7.4 
 
SI 5: Affinity Chromatography buffers 
 
 
 
 
 
 
SI 6: Affinity Chromatography profile of a non-induced culture. No peaks were 
detected in elution steps, meaning that expression system is strictly regulated by 
IPTG induction 
 
 
 
 
SI 8: Activity test for samples obtained after HPLC. Samples were not digested by 
LysC. No activity was detected meaning that peptides with leader peptide do not 
possess activity. Positive control: pure nisin. 
 
 
 
 
 
SI 8: Affinity chromatography profile of H-CinL-nisA modified by nisin system. 
This sample came from inclusion bodies. A peak was detected during the elution 
phase 
 
 
SI 9: HPLC profile of H-CinL-nisA of samples obtained after Affinity 
Chromatography. 
 
 
 
SI 10: HPLC profile of H-CinL-nisA modified by CinM after Affinity 
Chromatography. The clear peak at 20 min was proven be the target peptide. 
 
 
 
 
 
 
 
 
